Content
10/09/2024
San Francisco, CA USA
Amprion
completed $6 million Series B Round funding. Investors include
Formation Venture Engineering (lead), Eli Lilly and Company.
About
Amprion is a global leader advancing precision medicine for neurodegenerative disorders through seed amplification testing.
Amprion’s SAAmplify™-ɑSYN (formerly SYNTap®) Biomarker Test is a first-in-class, qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid the diagnosis of synucleinopathies such as Parkinson’s disease (PD), Lewy body dementia (LBD/DLB), and Alzheimer’s disease (AD) with Lewy body variant.
Startup
Sector:
MedTech
Healthcare
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
